Focus Partners Wealth Takes $547,000 Position in Guardant Health, Inc. (NASDAQ:GH)

Focus Partners Wealth bought a new stake in Guardant Health, Inc. (NASDAQ:GH - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 17,896 shares of the company's stock, valued at approximately $547,000.

Several other institutional investors have also recently added to or reduced their stakes in the business. NewEdge Advisors LLC increased its stake in Guardant Health by 13.5% in the fourth quarter. NewEdge Advisors LLC now owns 1,929 shares of the company's stock valued at $59,000 after purchasing an additional 230 shares during the last quarter. Summit Investment Advisors Inc. increased its stake in Guardant Health by 3.3% in the fourth quarter. Summit Investment Advisors Inc. now owns 12,346 shares of the company's stock valued at $377,000 after purchasing an additional 391 shares during the last quarter. Arizona State Retirement System increased its stake in Guardant Health by 1.1% in the fourth quarter. Arizona State Retirement System now owns 35,639 shares of the company's stock valued at $1,089,000 after purchasing an additional 403 shares during the last quarter. Jones Financial Companies Lllp increased its stake in Guardant Health by 43.5% in the fourth quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company's stock valued at $82,000 after purchasing an additional 817 shares during the last quarter. Finally, R Squared Ltd acquired a new stake in Guardant Health during the fourth quarter worth about $26,000. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Guardant Health

In other Guardant Health news, CEO Amirali Talasaz sold 106,784 shares of the business's stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $49.01, for a total transaction of $5,233,483.84. Following the completion of the sale, the chief executive officer now owns 2,202,672 shares in the company, valued at $107,952,954.72. The trade was a 4.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Over the last 90 days, insiders sold 107,132 shares of company stock valued at $5,248,393. Insiders own 6.10% of the company's stock.

Guardant Health Price Performance

GH traded up $0.95 on Friday, reaching $38.00. The company's stock had a trading volume of 1,373,039 shares, compared to its average volume of 2,145,131. The stock has a market cap of $4.71 billion, a price-to-earnings ratio of -10.67 and a beta of 1.49. Guardant Health, Inc. has a 1 year low of $20.14 and a 1 year high of $52.92. The business's 50 day moving average is $43.39 and its 200 day moving average is $40.24.

Guardant Health (NASDAQ:GH - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The company reported ($0.49) EPS for the quarter, beating analysts' consensus estimates of ($0.57) by $0.08. The firm had revenue of $203.47 million during the quarter, compared to the consensus estimate of $189.91 million. Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. Guardant Health's revenue for the quarter was up 20.8% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.46) earnings per share. As a group, research analysts forecast that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have commented on GH. TD Securities upped their price target on Guardant Health from $56.00 to $60.00 and gave the stock a "buy" rating in a research note on Thursday, May 1st. Stephens restated an "overweight" rating and set a $55.00 price target on shares of Guardant Health in a research note on Wednesday, March 26th. Raymond James restated an "outperform" rating and set a $59.00 price target (up from $39.00) on shares of Guardant Health in a research note on Friday, February 21st. UBS Group upped their price target on Guardant Health from $65.00 to $70.00 and gave the stock a "buy" rating in a research note on Thursday, May 1st. Finally, Guggenheim restated a "buy" rating and set a $56.00 price target on shares of Guardant Health in a research note on Monday, February 24th. Twenty-one equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Buy" and an average price target of $52.32.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.